<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03846479</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 18-1684</org_study_id>
    <nct_id>NCT03846479</nct_id>
  </id_info>
  <brief_title>Itacitinib for Low Risk GVHD</brief_title>
  <official_title>Itacitinib Monotherapy for Low Risk Graft-vs-Host Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John Levine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Graft-versus-host disease (GVHD) is treated with high doses of systemic steroids which can&#xD;
      lead to serious complications. A new blood test can identify patients whose GVHD is most&#xD;
      likely to respond to well to treatment (low risk GVHD). This study will test whether patients&#xD;
      with low risk GVHD can be successfully treated without steroids. Patients who participate&#xD;
      with this study will be treated with itacitinib instead of steroids. Itacitinib is an&#xD;
      experimental drug with an excellent safety record and appears to have activity as a GVHD&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 25, 2019</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Actual">May 7, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label, single arm, non-inferiority study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Minnesota standard risk clinical criteria</measure>
    <time_frame>Day 28</time_frame>
    <description>The Minnesota standard risk clinical criteria is defined as CR= complete remission, PR = partial remission, and TRM - treatment related mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ann Arbor Score 1 (AA1)</measure>
    <time_frame>Day 28</time_frame>
    <description>Ann Arbor Score - a scoring system that uses an algorithm of three biomarkers (TNFR1, ST2 and REG3a). A low Ann Arbor Score is Ann Arbor 1 (AA1) =&lt;10%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>Day 28</time_frame>
    <description>Number of adverse events at Day 28 to assess safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious infectious complications</measure>
    <time_frame>Day 90</time_frame>
    <description>The incidence of serious infectious complications in patients with GVHD treated with itacitinib. Serious infectious complications is defined as any viral and bacterial infections requiring treatment and proven fungal infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>Day 56</time_frame>
    <description>Number of overall response rate (ORR), defined as complete and partial responses.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Low Risk Acute Graft-versus-host Disease</condition>
  <condition>Graft-versus-host-disease</condition>
  <condition>GVHD</condition>
  <arm_group>
    <arm_group_label>Itacitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Itacitinib 200 mg administered orally daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itacitinib</intervention_name>
    <description>for up to 56 days</description>
    <arm_group_label>Itacitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed GVHD that meets criteria for Minnesota standard risk&#xD;
&#xD;
          -  Ann Arbor 1 GVHD by biomarkers&#xD;
&#xD;
          -  GVHD not previously treated systemically (topical therapies and non-absorbed steroids&#xD;
             are allowed)&#xD;
&#xD;
          -  Any donor type, HLA-match, conditioning regimen is acceptable&#xD;
&#xD;
          -  Age 12 - 75 years (children &lt;18 years must also weigh 50 kg or more)&#xD;
&#xD;
          -  Patients must be engrafted post-transplant (ANC &gt;500/Î¼L and platelet count &gt;20,000).&#xD;
             Use of growth factor supplementation to maintain neutrophil count is allowed.&#xD;
&#xD;
          -  Direct bilirubin must be &lt;2 mg/dL unless the elevation is known to be due to Gilbert&#xD;
             syndrome within 3 days prior to enrollment.&#xD;
&#xD;
          -  ALT/SGPT and AST/SGOT must be &lt;5x the upper limit of the normal range within 3 days&#xD;
             prior to enrollment.&#xD;
&#xD;
          -  Signed and dated written informed consent obtained from patient or legal&#xD;
             representative.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients currently being treated with any JAK inhibitor including ruxolitinib&#xD;
&#xD;
          -  Relapsed, progressing, or persistent malignancy requiring withdrawal of systemic&#xD;
             immune suppression&#xD;
&#xD;
          -  Patients with uncontrolled infection (i.e., progressive symptoms related to infection&#xD;
             despite treatment or persistently positive microbiological cultures despite treatment&#xD;
             or any other evidence of severe sepsis)&#xD;
&#xD;
          -  Severe organ dysfunction including requirement for dialysis, mechanical ventilation or&#xD;
             oxygen supplementation exceeding 40% FiO2 within 7 days of enrollment.&#xD;
&#xD;
          -  Creatinine clearance or estimated glomerular filtration rate &lt;30 ml/min as calculated&#xD;
             by institutional practice (e.g., Cockcroft-Gault equation, CKD-EPI equation, etc)&#xD;
&#xD;
          -  A clinical presentation resembling de novo chronic GVHD or overlap syndrome developing&#xD;
             before or present at the time of enrollment&#xD;
&#xD;
          -  Patients receiving corticosteroids &gt;10 mg/day prednisone (or other steroid equivalent)&#xD;
             for any indication within 7 days before the onset of acute GVHD except for adrenal&#xD;
             insufficiency or premedication for transfusions/IV meds&#xD;
&#xD;
          -  Patients who are pregnant&#xD;
&#xD;
          -  Patients receiving investigational agents within 30 days of enrollment. However, the&#xD;
             Principal Investigator (PI) may approve prior use of an investigational agent if the&#xD;
             agent is not expected to interfere with the safety or the efficacy of itacitinib&#xD;
&#xD;
          -  History of allergic reaction to itacitinib or any JAK inhibitor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Levine, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania, Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 17, 2019</study_first_submitted>
  <study_first_submitted_qc>February 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2019</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>John Levine</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Graft-versus-host disease</keyword>
  <keyword>Itacitinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

